iTechGuides is reader-supported. When you buy through links on our site, we may earn an affiliate commission. As an Amazon Associate I earn from qualifying purchases. Learn more
For most drug-discovery enzyme programs, start with directed evolution when you have a functional scaffold, a validated assay and enough screening capacity. Add AI design when screening is the bottleneck, when sequence or structure data can support a model, or when you need to search beyond close natural homologues. In practice, a hybrid design-build-test-learn loop is usually the most defensible choice: computational models propose or rank a focused library, while biochemical experiments establish what works under the project’s real conditions.
AI can reduce the number of variants you synthesize, but it cannot replace activity, selectivity, stability, expression or developability testing. Directed evolution measures phenotype directly, but may require testing thousands of variants. The right choice depends less on which label sounds newer than on your assay, starting scaffold, data quality, novelty target and laboratory throughput.
What the two approaches actually do
AI-designed enzymes
AI design uses sequence models, structure-prediction systems, protein-language models, generative models or machine-learning predictors to propose, score or prioritize amino-acid sequences. Depending on the workflow, the model may:
Free tools Windows power users keep installed
One-click scans. No signup required.
- Rank mutations around an existing enzyme.
- Suggest combinations of mutations that would be difficult to choose by intuition alone.
- Design focused libraries for a substrate, temperature, solvent or pH target.
- Identify distant homologues or propose de novo sequences outside the immediate natural sequence neighborhood.
- Estimate properties such as foldability, stability, expression or active-site geometry.
Those outputs are hypotheses, not demonstrated catalysts. A sequence that appears structurally plausible or scores well in a model still has to be synthesized, expressed and tested in the relevant biochemical assay. Folding accuracy and sequence plausibility do not establish catalytic activity, selectivity, pharmacology, manufacturability or clinical utility.
#1 Best Overall
- Read Before You Buy — No Video Output: These adapters support charging and USB 2.0 data transfer, but cannot transmit video signals. Except for standard USB webcams (which use USB data only), they are not compatible with HDMI/DisplayPort cables, video-capable USB-C hubs, or docking stations with video output.
- Convert USB-A Ports to USB-C: Designed to connect USB-C earphones, cables, flash drives, card readers, and other USB-C accessories to standard USB-A ports. Plug-and-play with no drivers or software required.
- Aluminum Alloy Housing: Built with a sturdy aluminum alloy shell that aids in heat dissipation and protects against daily wear and scratches. Designed to maintain a stable and secure connection.
- Compact & Travel-Friendly: The ultra-compact design allows the adapter to stay plugged into your device without blocking adjacent ports or adding bulk, reducing wear and tear on your original USB ports.
- 12-Month Warranty: Backed by a 12-month manufacturer warranty for peace of mind. Designed to meet strict quality control standards for reliable everyday performance.
Directed evolution
Directed evolution starts with a functional enzyme or a related scaffold. You create genetic diversity through methods such as targeted mutagenesis, recombination or error-prone PCR, then select or screen variants for the desired phenotype. The best performers become parents for another round.
Because the variants are tested experimentally, directed evolution measures the property that matters in the project’s actual assay. It can optimize activity, substrate selectivity, thermostability, solvent tolerance, expression and other traits simultaneously if the assay captures them. The trade-off is scale: a useful search can require experimentally testing thousands of variants, as described in a 2026 Protein Science review.
AI design versus directed evolution at a glance
| Decision axis | AI design | Directed evolution |
|---|---|---|
| Starting information | Benefits from curated sequence, structure or assay data; some methods can operate with limited experimental data but become less reliable. | Requires a functional starting scaffold and a measurable phenotype, but does not require a large training set. |
| How sequence space is searched | Computationally proposes, generates or ranks candidates, often concentrating experiments on a smaller library. | Samples experimentally through mutation, recombination and selection or screening. |
| Typical experimental burden | Can reduce synthesis and screening if predictions are informative; every candidate still needs laboratory validation. | May require thousands of variants and repeated assay cycles. |
| Novelty | Can explore distant homologues and de novo sequences beyond known natural neighborhoods. | Usually remains local to the starting scaffold, although recombination can broaden the search. |
| Dependence on assay quality | Models can rank candidates before testing, but an assay is still required to establish function and train useful project-specific predictors. | Depends directly on a robust selectable or screenable phenotype. |
| Main technical risks | Model bias, out-of-distribution sequences, inaccurate ranking, expression failure and activity that does not transfer from prediction to experiment. | Epistasis, incomplete library coverage, false positives or negatives in the assay and screening bottlenecks. |
| Best decision endpoint | Not just model score: activity, selectivity, stability, expression, solubility, manufacturability and drug-discovery developability. | The same endpoint, measured experimentally throughout the campaign. |
When directed evolution should be your first move
You have a validated high-throughput assay
If the assay reliably distinguishes useful from unusable variants, directed evolution converts laboratory throughput into search power. The assay should be quantitative enough to rank hits, reproducible across plates or runs, and relevant to the intended substrate and reaction conditions. A selectable phenotype can be even more powerful because growth or survival performs part of the filtering, but a screen is workable when selection is unavailable.
Do these 3 things before closing this tab:
1Repair Windows errors before they cause bigger problems2Fix the driver behind crashes, sound loss and screen glitches3Clear out junk files and repair common Windows errorsA starting enzyme already works
A measurable baseline gives every mutation a meaningful reference. This is especially valuable when the project needs incremental gains in catalytic rate, substrate selectivity, stability, expression, solvent tolerance or pH range. Evolution can preserve a known fold and active-site arrangement while improving the property that limits the program.
The target is optimization around an existing scaffold
Directed evolution is naturally suited to local optimization. If medicinal-chemistry work has already identified a substrate series and the enzyme accepts at least one relevant member, successive rounds can adapt the catalyst to analogues, improve turnover or reduce unwanted side reactions. The experimental phenotype includes effects that are hard to model, such as conformational dynamics, water networks and context-dependent epistasis.
You can build and screen the required library
Before choosing this path, estimate the number of variants your cloning, expression and assay systems can process at acceptable quality. The relevant capacity is not just the nominal plate count. It includes DNA construction, transformation efficiency, expression success, controls, replicate measurements, data handling and confirmation of hits. If the project cannot screen the library needed to cover its mutation strategy, AI-guided prioritization may be a better first addition than simply making a larger library.
When to add AI design early
Screening, not DNA construction, is the bottleneck
AI is most valuable when the laboratory can synthesize and test only a small fraction of the plausible sequence space. A model can rank mutations, propose a focused combinatorial library or select a diverse set that is less redundant than random sampling. The benefit is a reduction in experiments, not elimination of experiments.
Recommended Free Tools
Rank #2
- 5-in-1 USB-C Hub: Experience comprehensive connectivity featuring a Power Delivery input, two USB-A 2.0 ports, a USB-A 3.0 port, and an HDMI port. (Note: The USB-C power delivery input port is only for connecting an external wall charger to power your laptop and cannot power peripheral devices.)
- 90W Pass-Through Charging: Achieve optimal charging with 90W pass-through power to your laptop, supported by a total input of 100W, with the hub reserving 10W for operational efficiency. (Note: Wall charger not included.)
- Quick Data Transfers: Accelerate your productivity with rapid data transfers using a high-speed 5Gbps USB 3.0 port and two 480Mbps USB 2.0 ports.
- 4K HDMI Display: Enhance your visual experience with a hub capable of delivering 4K resolution at 30Hz in both mirror and extend modes. Please note that this hub is compatible with MacBook (macOS 12 and newer), Windows 10 and 11, ChromeOS, and laptops equipped with DP Alt Mode and Power Delivery. Note: This device is not compatible with Linux.
- What You Get: Anker USB-C Hub (5-in-1, 4K HDMI), welcome guide, 18-month warranty, and our friendly customer service.
You have usable sequence, structure or assay data
Model choice should follow the information available. A multiple-sequence alignment can support conservation and mutation-prioritization methods. A reliable structure or complex model can inform active-site geometry, substrate access and stability hypotheses. Historical assay data can support supervised ranking, provided measurements are comparable and failures have not been silently discarded. Sparse, noisy or inconsistent data can make a sophisticated model less useful than a simple baseline.
You need sequences beyond close natural homologues
De novo and generative methods can move beyond the local neighborhood that directed evolution normally explores. That matters when no natural enzyme has the required substrate scope, when the existing scaffold carries liabilities that are hard to remove, or when a new fold or architecture could offer a strategic advantage. The validation risk is higher because the model is asked to extrapolate rather than improve a known active protein.
Structural hypotheses can guide the campaign
AI or structure-based analysis can prioritize residues near the active site, channels, oligomer interfaces or flexible loops. It can also suggest variants for stability, solubility or expression before those traits become expensive downstream screens. Treat these as testable hypotheses: a predicted contact or stability gain does not prove the reaction mechanism has improved.
What the current evidence says about AI success
A 2024 Current Opinion in Structural Biology review states that “state-of-the-art design protocols now achieve experimental success rates nearing 20%.” That figure is an aggregate, task-specific result from defined protocols; it is not a universal probability that an AI-designed drug-discovery enzyme will work, nor is it a head-to-head comparison with directed evolution. Success definitions, enzyme classes, assay conditions and the number of candidates tested vary.
Capability is also uneven across protein architectures. A 2024 Nature Reviews Molecular Cell Biology review notes that “de novo design is still limited mostly to α-helix bundles.” Complex catalytic folds, large conformational changes, allosteric regulation and multi-component requirements remain harder than simpler design targets. A model can generate a sequence that folds while missing the geometry, dynamics or chemical environment needed for catalysis.
Computational generation can outpace experimental capacity. The practical bottleneck may shift from proposing sequences to synthesizing, expressing, purifying and testing them. Plan the laboratory validation queue before generating a large in-silico library.
How directed evolution succeeds—and where it stalls
It measures the project’s phenotype directly
Every round links genotype to an observed result under defined conditions. This makes directed evolution robust to physical effects that are poorly represented in training data, including epistasis, conformational exchange, solvent interactions and assay-specific substrate binding. If the assay is faithful to the intended use, the method optimizes what the program actually values.
Rank #3
- Sleek 7-in-1 USB-C Hub: Features an HDMI port, two USB-A 3.0 ports, and a USB-C data port, each providing 5Gbps transfer speeds. It also includes a USB-C PD input port for charging up to 100W and dual SD and TF card slots, all in a compact design.
- Flawless 4K@60Hz Video with HDMI: Delivers exceptional clarity and smoothness with its 4K@60Hz HDMI port, making it ideal for high-definition presentations and entertainment. (Note: Only the HDMI port supports video projection; the USB-C port is for data transfer only.)
- Double Up on Efficiency: The two USB-A 3.0 ports and a USB-C port support a fast 5Gbps data rate, significantly boosting your transfer speeds and improving productivity.
- Fast and Reliable 85W Charging: Offers high-capacity, speedy charging for laptops up to 85W, so you spend less time tethered to an outlet and more time being productive.
- What You Get: Anker USB-C Hub (7-in-1), welcome guide, 18-month warranty, and our friendly customer service.
Library design still determines what can be found
Random mutagenesis can waste capacity on inactive or poorly expressed sequences. Saturation mutagenesis at too many positions creates a combinatorial space that no practical screen can cover. Recombination can preserve useful combinations but may also break co-adapted interactions. Directed evolution is not a guarantee of global optimization; it is an experimental search whose coverage depends on library design and the number of variants tested.
Epistasis and assay artifacts can mislead rounds
A mutation that helps in one background may hurt in another. A fluorescent, growth-based or coupled assay may reward expression or stability rather than the catalytic property of interest. Include negative controls, parental controls, technical replicates and a confirmation assay that measures the reaction directly before promoting a hit.
The most defensible option: a hybrid design-build-test-learn loop
A hybrid campaign uses computation to make experiments more informative and directed evolution to keep decisions grounded in measured phenotype.
- Define the assay and constraints first. Specify substrate identity, concentration range, solvent, pH, temperature, cofactors, reaction time, acceptable product profile and the minimum activity or selectivity threshold. List developability requirements such as expression host, solubility, stability, aggregation, purification and manufacturability.
- Characterize the starting scaffold. Measure baseline activity, selectivity, expression and stability under the intended conditions. Record known liabilities and confirm that the assay has enough dynamic range to distinguish improved variants.
- Assemble and clean the data. Combine sequence, structure and historical assay results only when their conditions and endpoints are comparable. Preserve failed variants and assay metadata; removing failures can create a misleading training set.
- Use models to propose a tractable library. Rank single mutations, combinations or full sequences; enforce filters for obvious liabilities, diversity and synthesis feasibility. Include the parental enzyme, known active variants and deliberately diverse controls.
- Synthesize and test a representative subset. Do not test only the highest-scoring predictions. A diverse subset reveals whether the model is calibrated or merely overconfident in a narrow region of sequence space.
- Feed measurements into the next round. Update the ranking model or mutation strategy with activity, selectivity, stability, expression and failure data. Directed-evolution rounds can use the model to choose parents and positions; generative workflows can use the measured results as project-specific supervision.
- Confirm and de-risk hits. Re-express independent clones, repeat measurements and use an orthogonal assay. Test the full substrate panel, product selectivity, stability over the intended process window, solubility, aggregation and other drug-discovery developability criteria before declaring a lead.
How to choose by project condition
| Project condition | Recommended starting point | Reason |
|---|---|---|
| Functional scaffold, strong assay, ample screening capacity | Directed evolution first | Experimental selection can exploit real phenotype with less dependence on model extrapolation. |
| Functional scaffold, but screening capacity is limited | AI-guided directed evolution | Use models to prioritize mutations and reduce the library before experimental testing. |
| No useful scaffold, but rich sequence and structure data | AI-assisted exploration plus focused experimental validation | Computation can search distant homologues or de novo candidates, but the validation burden remains high. |
| Little sequence or structure data and no reliable assay | Improve assay and establish a baseline before either large campaign | Neither a model nor evolution can compensate for an endpoint that does not measure the desired function. |
| Need major novelty or a fold unlike known enzymes | AI design as a hypothesis generator, with conservative controls | Directed evolution is usually local to an existing scaffold; de novo exploration offers broader novelty at higher risk. |
| Primary concern is manufacturing or developability | Hybrid workflow with early developability screens | Do not wait until the end to discover that a highly active sequence is insoluble, unstable or difficult to produce. |
Drug-discovery endpoints that should govern the decision
Activity alone is an inadequate endpoint for an enzyme intended to support a drug-discovery program. Rank candidates against a predefined panel:
- Catalytic performance: turnover, apparent affinity, product formation and activity at the intended substrate concentration.
- Selectivity: desired regio-, stereo- or chemoselectivity, plus suppression of side products and activity on off-target substrates.
- Stability: thermal, storage, freeze-thaw, solvent and pH stability as relevant to the workflow.
- Expression and purification: soluble yield, host compatibility, purification recovery and batch-to-batch consistency.
- Solubility and aggregation: concentration limits, precipitation and behavior during formulation or reaction setup.
- Process fit: cofactor requirements, oxygen sensitivity, mixing, substrate loading and compatibility with downstream isolation.
- Developability: manufacturability, sequence liabilities, immunogenicity or other program-specific safety considerations, and the ability to scale the reaction.
AI can help prioritize these measurements, but it should not optimize a proxy while the real endpoint is ignored. Conversely, directed evolution can optimize whatever the assay rewards, including an artifact, unless orthogonal confirmation is built into the campaign.
Quick wins for a faster PC:
Repair Windows errors before they cause bigger problemsFix Now →Fix the driver behind crashes, sound loss and screen glitchesFind Drivers →Cost, calendar time and evidence limits
There is no reliable universal winner on cost or elapsed time. The available literature does not provide a standardized, head-to-head statistic for AI-designed enzymes versus directed evolution that controls for enzyme class, assay, library size, success definition and geography. A claim that one method is always cheaper or faster is therefore a project-specific hypothesis, not an established fact.
AI shifts spending toward data curation, model selection, compute, sequence synthesis and validation of predictions. Directed evolution shifts spending toward library construction, expression, screening capacity, hit confirmation and repeated rounds. A hybrid approach adds computational work but can lower the number of variants that reach the laboratory; whether that is economical depends on the relative cost and throughput of each step.
Rank #4
- Dual Converters, Infinite Potential：Includes 2× USB C male to USB A female adapters and 2× USB A male to USB C female adapters. Perfect for a wide range of uses—tablets with Bluetooth keyboards, expand USB ports on macbook, and more. Two different converters for all your daily needs
- Next-Level 10Gbps & 3A Charging: No more slow 480Mbps, this usb to usb c adapter has a transfer speed of up to 10Gbps, allowing you to do more transferring in less time. This usb adapter fits both USB A and USB C charger, supporting up to 3A fast charging
- Upgraded Exquisite Craftsmanship: With an aluminum alloy housing and metal connector, the usbc to usb adapter is extremely durable and sturdy. Rigorously tested to withstand more than 10,000 times of plugging and unplugging, ensuring long-lasting performance
- Broad Compatible: The usb c to usb adapter widely supports all USB C/ USB A devices like laptops, tablets, cellphones, car chargers, and phone chargers. Such as compatible with MacBook Pro/Air 2023/2022, Thunderbolt 4/3 Devices,Apple MagSafe Watch 9/8/7/SE/Ultra, iPad Pro 2022/2021, Samsung Galaxy S23/S20/S10, and iPhone 17/16/15 Pro. Plug and play
- Please Note: To reach 10Gbps speed, keep the cable under 3.3 ft. For USB A Male to USB C adapters, try flipping the USB C connector. USB C Male to USB A adapters support bidirectional 10Gbps transfer within 3.3 ft
Make the comparison with a project ledger rather than a slogan. Estimate:
- Cost and lead time for DNA construction and synthesis.
- Expression and purification throughput, including failed constructs.
- Assay cost per variant, replicate requirements and confirmation rate.
- Computational and data-curation effort.
- Expected number of rounds or model updates.
- Cost of late discovery of poor stability, selectivity or manufacturability.
Use measured hit rates and confirmation rates from your own pilot library to update the estimate. Do not transfer the 20% AI figure to a different enzyme class or treat a literature screening count as a prediction for your program.
Windows Errors? Fix Them Before They Spread
Repair common Windows errors and clear accumulated junk for a smoother, more stable PC - no reinstall needed.Free scan · no reinstallCrashes, No Sound, or Screen Glitches?
Random freezes, missing sound and display glitches usually trace back to one bad driver. Find and replace yours safely.Free scan · under a minuteCommon failure modes and practical fixes
AI ranks sequences that do not express
Likely causes: out-of-distribution sequences, weak expression predictors, aggregation or synthesis constraints ignored during design.
Fix: add expression and solubility filters, constrain generation to experimentally observed sequence space where appropriate, and include expression measurements in the next model update. Keep a diverse control set so a ranking failure is visible rather than hidden.
AI designs fold but have no catalytic activity
Likely causes: incorrect active-site geometry, missing conformational dynamics, unsuitable protonation or solvent environment, or a model objective that rewards foldability rather than catalysis.
Fix: test active-site and substrate-binding hypotheses experimentally, include structure-informed diversity, and prioritize direct reaction assays over proxy scores.
Directed evolution finds activity that does not generalize
Likely causes: assay interference, altered expression, a coupled readout that rewards the wrong property or a mutation that works only at one substrate concentration.
Best Value
- 5-in-1 Connectivity: Equipped with a 4K HDMI port, a 5 Gbps USB-C data port, two 5 Gbps USB-A ports, and a USB C 100W PD-IN port. Note: The USB C 100W PD-IN port supports only charging and does not support data transfer devices such as headphones or speakers.
- Powerful Pass-Through Charging: Supports up to 85W pass-through charging so you can power up your laptop while you use the hub. Note: Pass-through charging requires a charger (not included). Note: To achieve full power for iPad, we recommend using a 45W wall charger.
- Transfer Files in Seconds: Move files to and from your laptop at speeds of up to 5 Gbps via the USB-C and USB-A data ports. Note: The USB C 5Gbps Data port does not support video output.
- HD Display: Connect to the HDMI port to stream or mirror content to an external monitor in resolutions of up to 4K@30Hz. Note: The USB-C ports do not support video output.
- What You Get: Anker 332 USB-C Hub (5-in-1), welcome guide, our worry-free 18-month warranty, and friendly customer service.
Fix: re-express independent clones, repeat the primary assay, measure product directly and test the intended substrate and process window.
Library coverage is too shallow
Likely causes: too many mutable positions, combinatorial explosion or a screen smaller than the designed diversity.
Fix: reduce the position set using structural or conservation evidence, use focused degenerate codons or recombination, and let an AI model prioritize a subset that the laboratory can actually test.
What’s actually slowing this PC down?
Pick the symptom - the matching free tool is one click away.
Rounds improve activity but damage developability
Likely causes: selection pressure focused on one metric while stability, solubility or expression were treated as afterthoughts.
Fix: use multi-objective ranking or counter-screens from the first practical round. Retain variants that meet the activity threshold without creating unacceptable liabilities.
A decision checklist for a project team
Before committing to a platform, answer these questions in writing:
- Do we have a validated, quantitative assay or selection that reflects the intended reaction?
- Is there a scaffold with measurable activity on the relevant substrate?
- How many variants can we construct, express and test per cycle with controls and replicates?
- Which sequence, structure and assay data are available, and are their conditions comparable?
- Is the goal local optimization or genuinely novel sequence space?
- Which properties must be co-optimized: activity, selectivity, stability, expression, solubility or manufacturability?
- What is the confirmation assay, and what result qualifies as a real hit?
- What evidence would make us stop using a model or change the mutation strategy?
If the assay and scaffold are strong but screening is abundant, directed evolution is the lower-risk starting point. If screening is scarce and the data support prediction, add AI to focus the search. If novelty is essential and no scaffold meets the requirement, use AI to generate hypotheses while budgeting for a larger experimental validation burden. In all three cases, measured biochemical performance—not a model score or a method label—should decide which enzyme advances.
Quick Recap
Product prices and availability are accurate as of the date/time indicated and are subject to change. Any price and availability information displayed on Amazon at the time of purchase will apply.
